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The dissertation summarizes the drug-related death phenomenon in the UK 
emphasizing England and Wales and compares the figures with international 
development, particularly in the EU. Legal regulation, in particular the Misuse 
of Drugs Act of 1971 and its amendments strive for classifying drugs and label 
illicit drugs or their exceptional use. Moreover, legislation gives us a bundle of 
measures to investigate drugs misuse and especially drug-related deaths, allo-
cating the duties of the police, coroner and judiciary. 
 
Opiates, especially heroin, cocaine and stimulants are still the major drugs in-
volved in the UK, which largely – with the exception of cocaine – reflects the 
situation on the continent. The distribution of age of death shows a tendency 
from the range of 20 to 30 years towards men in their forties during the last 
decades. Overall, the UK, Scandinavia and the Baltic states have leading num-
bers drug-related deaths. New Psychoactive Substances are a new challenge in 
Europe but the UK may be especially affected by this unfortunate wave. All 
authorities world-wide have to deal with this "hydra" of new psychoactive sub-
stances (NPS) due to infinite chemical variations and unlimited supply. Never-
theless, heroin and cocaine still belong to the most noxious drugs with regard 
to the fatal outcome.  
 
The problem of drug-related deaths starts with the neurobiology of addiction 
including cerebral reward cycles which disinhibit prefrontal control, leading to 
craving and drug intake, even if severe somatic damage occurred. This fatal 
course does not depend on a particular drug but may be concerned as the final 
part the fatal reward pathway. In general, noradrenalin, serotonin and dopa-
mine are involved, although some drugs may act on specific receptors such as 
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opiates or cannabinoids. Unfortunately, the pharmacology of the NPSs is often 
not well known, and this lack of information will increase the risk of drug-
related deaths or delinquency in future.   
 
Autonomy, paternalism and liberty form a field of tension in democracy, so 
that preventive measures must respect individual rights. Restrictive strategies 
alone show a limited success. It will be the concerted action of law, judiciary, 
police, science, educators, social work and medicine among others to strength-
en future generations. We struggle hard against drugs and the sequelae but we 









In August 2017 the BBC reported on the serious drug problem in England and 
Wales: “Drug deaths: Cocaine contributes to record number”.1 The BBC cited 
data of the ONS (Office for National Statistics) and stated that 3.774 people 
died due to use of legal and illegal drugs, which was the highest death rate 
since 1993. 371 died following use of cocaine, corresponding to a rise of 16%. 
Surprisingly, the major affected age groups were men between an age of 30 
and 49 years. The authors suggested that the quality (“purity”) of street drugs 
has improved in combination with the foundation of “shooting galleries” [or 
“crack houses”] – meeting points – and the recent promotion of the “Legal 
Highs” could be responsible for the evil development. New Psychoactive Sub-
stances (NPS) and fentanyl as well as hepatotoxic paracetamol were also in-
creasingly involved in drug deaths, heroin or morphine being still on top of the 
list with 1.209 deaths in 2016. The article postulated treatment as the approach 
of choice and rejected criminalization of the persons affected.  
 
The problem is not only virulent in the UK, but a world-wide issue, which is 
going to deprive a generation of their future. Nobody has the “magic pill” to 
solve the problem. However, it is worth thinking about the problem, discussing 
it with experts, offer treatments, and what is most important, never giving up to 
save lives. I hope that the following work mediates an idea of the problem and 
supports our mutual efforts to stop this awful trend. 
 
2  Definitions and Epidemiology 
 
Drug-related deaths are defined are deaths for which illicit drug use is the ma-
jor underlying cause, although the definition may vary in the scientific litera-
ture. We talk about deaths which can be in drug misusers, addicted, suicides, 
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homicide, accidents and so on.2,3 We are aware of the fact that some cases may 
be overseen due to uncertainities of the death certificate, but the data of the UK 
in comparison international data gives us an idea to cope with problem and if 
possible helps us to make adequate medical and political decisions. The rela-
tion between drug and death may be irrational (e.g. intoxication) or rational 
due to the medical use (e. g. chemotherapy, HAART). The compound may be 
legal (prescription, OTC, glue or thinners) or illicit (e.g. heroine, crocodile), 
may be taken deliberately (suicide) or accidentally (e. g. due to false dose or 
compound).  
 
In a specific statistics Public Health England (2016) analyzed trend of drug re-
lated deaths between 1993 and 2004.4 They found a tremendous increase in 
mortality with a peak in 2000 (summed up: 6101 men and 2055 women). Most 
deaths were related to drug abuse or dependence (m 48.1% or f 31.0%) and ac-
cidental poisoning (m 34.9 or f 28.9 %). Interestingly, self-poisoning was more 
frequent in women (22.5 %) than in men (7.5 %). In this paper the most inflict-
ed group were men between 25 and 39 years old, but a trend to “older” age 
groups was already vaguely perceptible during this period. The authors calcu-
lated the Years of Life lost (YLL) before 55 years, this number increased from 
11.7 to 18.9 years in men, and from 2.6 to 4.4 years in women which quite 
alarming. The following drugs topped the list in males:  Heroin/morphine (48 
%), methadone (22 %), benzodiazepines (15 %), opiates (9) and cocaine (6) 
with more than 700 deaths each.  
 
The ONS (Office for National Statistics) statistics includes legal and illegal 
drugs – not alcohol - and recorded an increase predominantly for males aged 
40 to 49 of mostly accidental deaths during the last decade in England and 
Wales (Fig. 1).1 The changes were relatively constant, the rate of deaths even 
decreased in those aged 20 to 29 years. In 2017 (table 1) opiates (n=2038) were 
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the leading problem followed by benzodiazepines (n=406) and antidepressants 
(n=406), cocaine (n=371) or amphetamines (n=160). What is remarkable in 
comparison with the above study: Those dying from drug-related deaths are 
getting older! Could it be that preventive measures are of use in the younger 
generation? 
 
Moreover, the increase of deaths due to NPS (new psychoactive substances) 
from 55 to 123 deaths between 2012 and 2016 is a worrying world-wide de-
velopment, which did not play such a relevant role in 1990ies.  
 
Drug related deaths are for sure a leading challenge for the country also in rela-
tion to EU-partners. What is astonishing – for me as a psychiatrist – is the high 
rate of deaths due to antidepressants, as modern compounds (SSRIs) should be 
safer than tricyclics in former times. Moreover the high numbers of deaths with 
regard to benzodiazepines let suspect combinations of drugs. Also cocaine, an 
"old stuff", obviously “celebrates” some kind of a bad revival. 
 
The corresponding death rates of Scotland and Northern-Ireland are given in 
Tables 2 and 3 as well as in figure 2. We realize a substantial increase of deaths 
between 2006 and 2016 in Scotland. Opiates also dominate in these parts of the 
country, and deaths due to cocaine rise, too, although not as marked as in Eng-
land and Wales. However, antidepressants, NPSs and particularly benzodiaze-
pine derivates become more and more important. Particularly, etizolam has 
gained importance during the last years. Interestingly, the deaths due to parace-
tamol – low therapeutic index! – could be almost eliminated in Northern-
Ireland.     
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In order to have some kind of external control, I compare the British data with 
those of the 3 equivalent countries: Germany, France and Italy. The European 
drug report 2017 allows us a comparative view on drug data.5 
  
- In the UK we have 11.3 % users of cannabis aged 16-34 years, cocaine 
comes to 4 %, MDMA to 3 % and amphetamines to 0.9 %. High-risk opiate 
users (heroin) total up to 330446 users. 
 
- In Germany – alike population – we find 13.3 % cannabis users, ampheta-
mine 1.9 %, MDMA 1.3 % and cocaine 1.2 %. High risk opiate users total 
up to 160322. 
 
- In France the cannabis is consumed in 22.1 %, cocaine in 2.4 %, MDMA in 
2.3 % and amphetamines in 0.7 %. 211000 users take high-risk opiates. 
 
- In Italy the numbers are 19 % for cannabis, 1.8 % for cocaine, 1 % for 
MDMA and 0.6 % with regard to amphetamines. 205200 use high risk opi-
ates.  
 
If we include the drug-related death rates in figure 3, it is really astonishing 
that Germany and the UK “lead” the rates, although the frequency of low risk 
drug consumers is lower in both countries compared to Italy and France. How-
ever, high-risk consumers are highly frequent in the UK. France and the UK, 
on the other side, offer more substitution treatments (i. e. 168840 and 142085 
treatments, respectively) compared to Germany or Italy. We shall try to differ-
entiate this paradoxon in the prevention section.  
 
In table 4 the figures of different countries are summarized. The drug-related 
death rates of the Baltic States and Scandinavia and Scotland turn out to be ex-
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tremely high compared to the average figures of the EU. On the contrary, the 
death rates in France, Italy or Belgium are apparently much lower than in other 
countries. What attracts my attention is the low number of death rates in the 
Netherlands, although the country is known for its liberal drug policy.  
 
3 Legal Aspects 
 
Laws and regulations 
 
Several specific drug laws regulate use or misuse of drugs in the UK e.g. the 
Misuse of Drugs Act (MDA) in 1971, the Medicines Act in 1968 or the Psy-
choactive Substance Act in 1976.6,7  However, other laws (e. g. the Road Traf-
fic Act, Clinical trial regulations, the Medicines Act of 1968 and EU drug 
regulations, patent laws, the Children and Young Person Act of 1933) may 
have an influence on the use of drugs. The MDA classifies - and restricts pos-
session, commerce and regulates penalties - the compounds according to 3 
groups:  
 
Class A compounds are dangerous (e. g. cocaine or MDMA, mushrooms, in-
jected Class B drugs), 
  
Class B compounds such as amphetamine, cannabis or codeine are legal for 
certain purposes (amphetamine - ADHS, severe pain-cannabis (SativexR, 
DronabinolR) but also widely used as illegal drugs (amphetamine = speed, 
cannabis = marihuana), and  
 
Class C drugs which include anabolic steroids or ketamine, even benzodiaze-
pines and liquid ecstasy [used as SomsanitR, a narcotic, in some countries).  
 
page 14 of 76 
 
The allocations of drugs may vary from time to time and is also influenced by 
social attitude (e. g. cannabis is now legal for treatment of severe pain in Ger-
many (personal communication). The Temporary Class Drug Order (2011) 
amended the MDA of 1971 and allowed the Home Secretary to add any dan-
gerous substance (e. g. NPSs) transiently to the list in order to keep in step 
with illegal drug labs. The penalties which can be given for drug offences are 
summarized in table 5. The legislation may be – in theory – a bit clearer than in 
Germany. Possession of small amounts of drugs alone, according to my expe-
rience, is generally not prosecuted in Germany and the influence of this philos-
ophy remains open. The Netherlands, where cannabis is offered in coffee 
shops, was and is very attractive for addicted from adjacent countries. 
 
In 2001 a more detailed classification (schedule 1-5) was introduced:  
1: no medical use – LSD [except rare experimental trials in psychotherapy in 
Switzerland, personal communication], opium, psilocybin, coca leafs 
 
2: possession without prescription not allowed- amphetamine, cocaine (some-
times used as local ophthalmological anaesthetic), morphine, methadone 
 
3: prescription necessary – barbiturates, flunitrazepam, temazepam 
 
4: a: minor tranquillizers without prescription 
4: b: possession allowed, dealing forbidden: anabolic steroids 
 
5: corresponding to OTC (over the counter) products 
 
Should a product be used for another indication one speaks of "off-label use", 
which requires a special informed consent (e. g. ketamine nasal spray in de-
pression). Compassionate-use (e. g. thalidomide in a patient with glioblastoma 
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some years ago – inhibition of vascularisation) is the administration of drugs 
under development (phases I to III/IV) or not approved drugs. These uses (to 
the best of the patient) demand a high standard of diligence and comprehensive 
information. However, unlicensed drugs for children are quite usual and they 
are of course ethically absolutely indicated.  
 
The Coroner´s and Procurator´s Fiscal duties 
 
The historical difference between the UK and the continent may be reflected 
by the coroner´s system. Even translation of famous literature (e.g. Jenny 
Cooper of M R Hall: “The coroner” was changed to “Death certificate - 
Totenschein”) causes problems. The coroner [procurator fiscal in Scotland, PF] 
is an independent official – about 100 professionals in England and Wales – 
who has to answer with his staff the question about unexpected deaths – often 
referred by a doctor – the following questions:  
Who is the person?  
When, how and where did he/she die?7   
 
He/She can start an inquest and order an autopsy, depending on the circum-
stances (unnatural death, violence, unknown course, prison etc.). Drug-related 
deaths are an integral part of his duty. The inquest [“fatal accident inquiry” in 
Scotland] is done public – in general – and a jury with 7- 11 members may be 
appointed. In complex cases - mass  accidents - the coroner may supported by 
a special "Identification Commission". The recommendations – not really legal 
liability since the criminal law act 1977- may lead to a judicial processing and 
often the verdict of the coroner is confirmed by the judge. In this regard the 
coroner is part of the CPS (crown prosecution service), but the coroner has also 
the aim, to prevent similar fatal developments. Although normally restricted to 
his/her region [the coroners regulation of 2013 allows the coroner to pursue a 
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case beyond the “borders”], the coroner may also investigate cases from 
abroad, which is, on the contrary, never done by the procurator fiscal. As a 
rule, the PF is a lawyer, whereas the coroner could also be a doctor. According 
to the Coroner´s and Justice Act 2009 the future coroners will be lawyers, only. 
The PF can, in contrast to the coroner, initiate a legal process on behalf of the 
Lord Advocate. Moreover, the balance of probabilities leading the coroner´s 
verdict is the duty of Sheriff (judge) in Scotland and not the primary duty of 
the PF.  
 
4 Psychology and neurobiology of drug abuse 
 
A lot of drug users are quite young humans, which is a tragedy, as brains in a 
developmental state are very susceptible for chronic harm of the brain and 
therefore future cognitive impairment. In adolescence especially boys have the 
feeling of “sensations seeking” on the one side, and boredom on the other 
side.8 They look for some kind of thrill and new experiences and have difficul-
ties to fill the time with reasonable activities. Some dysbalance of neurotrans-
mitters, particularly noradrenaline, may be responsible. The PFC (prefrontal 
cortex) is not yet fully developed at an early age – integrative center with re-
sponsibility for executive foresightful thinking - and therefore teenagers, par-
ticularly lads, are not able to fully control their motivation. This age, however, 
is the time in which most of the addicts start.9 In addition, the reward system, 
i.e. including the Ncl. accumbens, plays a major role especially for young 
adults with regard to risk behavior.10 
 
In modern neurobiological hypotheses dopamine in the limbic regions, particu-
larly in the Ncl. accumbens (Nac) and the ventral tegmental area (VTA) is an 
important issue. The following connections are relevant for the addiction pro-
cess:11, 12, 13, 14  
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- Stimulants directly inhibit re-uptake of dopamine in the Ncl. accumbens 
(Nac) (and also in the Amygdala),  
- opiates activate via interneurons the Nac, Amygdala and VTA (ventral teg-
mental area), the latter facilitates release of dopamine in the Nac 
- alcohol acts via GABAa on the VTA, the Nac and the Amygdala, leading to 
release of dopamine (note: it also said to facilitate secretion of opioidergic pep-
tides in these regions) [note: Opiate-antagonists such as naltrexone reduce 
craving in alcoholism] 
- nicotine activates Ach-receptors in the VTA, the Nac and the Amygdala, and 
possibly also release of opioidergic peptides 
- THC activates CB1-receptors in the VTA the Nac and the Amgydala and fa-
cilitates secretion of dopamine 
 
Dopamine facilitates the motivation to seek the anticipated reward and condi-
tional learning, e.g. the salience of special trigger factors or environments. In 
case of addiction, these mechanisms cause long-term habituation of the dopa-
mine effect, longer than they do after natural positive stimulations -e. g. mo-
ments of happiness-, which also need lower concentrations of dopamine. If this 
is the case, some kind fatal addiction circle – craving binging  withdrawal 
conditional response - is initiated. The most important structures involved in 
this neurocircuit are given in Figure 4. One distinguishes 3 separate stages of 
addiction:14 
  
- Preoccupation/anticipation: The PFC (prefrontal cortex) is impaired, gluta-
mate concentrations increase, and impulsive craving behavior is facilitated 
as the PFC does not “stop” sufficiently impulses 
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- Withdrawal/negative affect: Stress neurotransmitters are activated 
(Corticotropin, dynorphin) in the Amygdala. The addicted longs for the 
drug to get rid of the negative feelings 
 
- Binge/intoxication stage: The reward circuit (Nac) with dopamine and en-
dogenous opiates is upregulated and triggers craving and substance seeking.  
 
This model explains the effects of alcohol and other drugs on the brain and 
useful to understand that the addicted has a lot difficulties to withstand further 
intake of the drug.  
 
5 Toxicology and Drug-effect relation  
 
In order to classify the risk potential of a drug, several measures have been in-
troduced.15 The LD50, i. e. the dose which leads to death in 50% of the animals 
(or analogously the ED50, i. e. the dose where 50 % of a population come at a 
wished effect) has been a popular measure to characterize the dose-mortality-
relation of a drug in animal tests. Table 6 gives us a hint that intoxications with 
diazepam or THC may be less dangerous than heroine or even nicotine. The 
principle of the method to determine the LD50 is shown in figure 5 using clini-
cal routine data of extrapyramidal side effects of antipsychotics. The ED50 in-
forms us about the dose which provokes a specific wished event. The OECD 
(OECD guidelines) has classified acute oral toxicity of compounds based on 
LD50 values as follows:16  
LD50 <=25mg/kg – very toxic,  
LD50 26 mg/kg <= 200 mg/kg – toxic,  
LD50 201 mg/kg <=2000, and  
LD50 > 200 mg/kg – unclassified 
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We are aware that illegal drugs may be very toxic indeed, especially if no data 
are available such as in NPSs. Meanwhile, the acute toxic class method - or al-
ternatives- has replaced LD50 classification, as the sequential testing methods 
reduce the number of animals in the EU and USA.17  
 
In clinical terms, the ratio ED50/TD50 (TI, therapeutic index) is used as a 
measure of drug safety in practice.15  E. g. the ED50 for morphine (pain) is 
roughly 10 mg, the TD50 for respiratory depression is 60 mg (for human, 70 
kg), corresponding to a TI of 6, which is quite acceptable. Many more charac-
teristics have been introduced in clinical toxicology - especially for long-term 
use - e. g. NOEL, NOEC which characterize toxicity of chronic and subchronic 
administration but are beyond the scope of the dissertation.18  Table 6 summa-
rizes some LD50-values to get a “feeling” for the toxicity of some com-
pounds.19 
  
Lachenmeyer et al. used the MOE approach (margin of exposure) – European 
research project - to assess the risk of a drug, which is not identical to toxici-
ty.20  Briefly, the method uses toxicological threshold doses in relation to (sup-
posed) human intake rates and integrates animal MLDs (mean lethal doses) in 
a Monte-Carlo model. High risk drugs for individual users are alcohol, cocaine, 
nicotine and heroine, “mean” risk drugs are stimulants, opiates or benzodiaze-
pines. Cannabis was assessed as a low risk drug. Alcohol and nicotine have a 
tremendous prevalence indeed. In other words, the overall predominant risk for 
a citizen to die from a drug remains very high for alcohol and nicotine. 
 
6 Pharmacokinetics – routes of administration 
 
As a clinician I see every – even peculiar – ways to administer illicit drugs (via 
urethra e. g) including abstruse methods to hide the intake, exchange of urine 
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or passports. The coroner and toxicologist need a lot of imagination to 
distangle the way of drug consumption. 
 
Three ways are rather common: oral intake, intravenous injection and inhala-
tion.21,22  Sometimes, subcutaneous/intramuscular administration or from time 
to time rectal and nasal spray applications, and - as an exception- transdermal 
systems (e. g. fentanyl) are used by consumers. LADME (Liberation, Absorp-
tion, Distribution, Metabolism, Elimination) is the acronym, which is im-
portant to understand how the drug reaches body compartments to become ef-
fective. Liberation means that the formulation must be disintegrated before it 
can be absorbed. The extreme variant is body packing (or stuffing), in which 
the drug (e. g. cocaine from South America) is – deliberately - not set free. No 
liberation, no drug in the body. But this may be a fatal deception for the 
“bodystuffer”, if the container rips. 
  
Absorption then can take place depending on the site and physicochemical 
properties of the stuff. Intravenous administration may be an exemption, as the 
drug directly enters the blood compartment. Very rapid absorption is observed 
after inhalation (e. g. THC joints) or nasal (e. g. ketamine) administration with 
latencies of some minutes. After oral or rectal (or vaginal) application 30 to 60 
minutes may be a rule of thumb until the effect starts. However, liposolubility 
or pk-values (acid-base-property) can alter absorption dramatically. KCN (po-
tassium cyanide) is lethal (HCN!) within minutes in acidic stomach, but not in 
case of anacidity as potash lye (KOH) is formed.  
 
Distribution depends very much on liposolubility. A good example is cannabis 
which can be distributed into fat tissue from which it can be released for sever-
al months onward. A clinical example is diazepam, which is re-distributed in 
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fat tissue after intravenous injection causing a very short fictive half-life of 10 
to 20 minutes.  
 
Metabolism depends on the structure of the molecule (e.g. N2-groups, -SH-
groups, OH-groups) or whether specific enzymes exist.23  Phase I metabolism 
adds such functional groups. Phase II reactions often bind endogenous sub-
strates (conjugates) to the polar compounds such as glucuronic acid, sulfuric 
acid or acetic acid, in order to accelerate elimination. Phase I reactions are of-
ten mediated via Cytochrome P450 isoenzymes (e. g. 2D6, 3A4 etc.) which can 
be induced or inhibited. A practical example was a man taking oxycodone who 
also obtained paroxetine with an overwhelming effect. Due to inhibition of 
2D6 due to paroxetine the oxycodone concentration increased up to toxic lev-
els. Such interactions can be fatal and it is important to ask anybody whether 
he is taking illicit drugs as well (personal experience).   
 
Alcohol (in normal doses) is degraded by the ADH via a linear zero-order ki-
netics, however, MEOS (microsomal ethanol oxidizing system) can be induced 
following chronic abuse. Other compounds such as THC are hydroxylated, 
glucuronidated or carboxylated usually following Michael-Menton kinetics. 
Some metabolites are active, others are inactive.24  Sometimes prodrugs must 
be metabolized to become active;  a relevant example may be codein, which 
has to be demethylated to morphine. One metabolism is clinically extremely 
important: the combination of alcohol and cocaine. The metabolite coca-
ethylene is highly toxic with lethality rate some 20 times increased compared 
to cocaine and leads to seizures and liver damage.25  
 
Elimination is the final process to excrete the compound from the body.24  The 
kidney may be the most important organ, but exhalation via the lungs, excre-
tion via bile or feces, even via skin (sweat, hair) or salivary may suitable for 
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diagnostic of illegal drugs. Excretion often follows an exponential decrease 
(first order kinetics), so that half-life can characterize excretion, i.e. after 5 
half-lives the drug may be roughly considered as eliminated. Of course, physi-
cochemical properties are substantial especially for renal excretion: Acids such 
as barbiturates are better excreted in alkaline environment and, vice versa, am-
phetamines are better excreted in acidic milieu. In Table 7 basic metabolic and 
kinetic data of some drugs are summarized.  
 
7 Some notes concerning drug detection 
 
A very simple test for drugs is the DrugWipe-Test, which detects cannabis, co-
caine, opiates and amphetamine derivatives in saliva or sweat.26 It is based on 
an antibody-antigen (drug) reaction. A analogous mechanism characterize drug 
screening tests in urine, which in general also include barbiturates and some-
times PCB.27 With regard to alcohol the breath test is in use since the 1950ies 
and was developed by Mr. Borkenstein, a police captain from Indiana.28 The 
principle has remained the same, i. e. the degradation of potassium dichromate 
K2Cr2O7- measured via a spectrophotometer - correlates with the amount of 
alcohol, which is itself oxidized to acetic acid (HAc). Many color tests exist 
(for cocaine, stimulants, barbiturates, Marquis-test for opiates, van Urks test 
for psilocybin and psilocin), which could be completed by thin-layer chroma-
tography, gas chromatography or UV-spectroscopy and IR-spectroscopy. Very 
sophisticated procedures are the Gaschromatography-Mass spectroscopy 
(GC/MS) or the HPLC (high pressure liquid chromatography for real quantita-
tive analysis.28,29 The toxicologist has an arsenal of methods to support the fo-
rensic team.  
 
Some pitfalls can nevertheless arise. After intake of THC the metabolite 9-
carboxy-THC is relevant in urine, not the mother compound. Heroin is rapidly 
page 23 of 76 
 
metabolized to monoacetyl-mophine and morphine, therefore heroin disappears 
quickly. So both metabolites prove the intake of morphine. In case of doubt, 
vitreous humor can be analyzed, where monoacetyl-mophine is degraded re-
markably slower.28 For particular purposes drugs can be looked for in stomach, 
organs (e. g. talc crystals or cotton fibers after use of heroin), bile, stool, hair 
(time of intake can be estimated), intraocular fluid or even in insects or their 
maggots.  
 
Very important is to consider – on duty - the short half-life of “liquid ecstacy” 
(GHB gamma-OH-butyric acid).27,30 After 12-24 hours the samples were 100 
% below the limit of detection.  The samples (plasma, urine) should be collect-
ed as soon as possible, as the drug is metabolized an intruded into the Krebs-
cycle. Perhaps a glucuronide may improve – will be longer detectable- the 
analysis in future.31 As it paramount importance, some critical detection limits 
in urine drug screening tests, the following paragraphs gives us the approxi-
mate latencies for some frequent drugs in urine tests.27 
 
- Amphetamines 2-5 days, Methamphetamine 5-7 days 
- Ecstacy 5-7 days 
- Barbiturates 3-4 weeks (long acting compounds) 
- Benzodiazepines 7-10 days (midazolam 0.5 days!) 
- Cannabinoides 5-60 days (the detection latency increases with time of use. 
5 days after single use, up 60 days after 6 weeks daily use)  
- Cocaine 1-4 days (metabolites) 
- PCP (phencyclidine) 2-4 days 
- LSD 7-10 days 
- Ketamine 5-7 days 
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We learn from this simple data to take urine as soon as possible without hesita-
tion in the emergency room - when feasible. 
 




Opiates such heroin or morphine bind to classical opioid receptors on the sur-
face of cells (e. g. CNS and spinal neurons, smooth muscle) µ [exactly: µ1 
presynaptical and µ2 postsynaptical], δ and κ [note: recently also orphan recep-
tors and ε-receptors have been found].32,33 The binding on receptor site is fol-
lowed by an activation of pathway (cascade) including Gi-proteins ("transduc-
er) and cAMP (inhibition of adenylate cyclase) or ion channels and neuro-
transmitters. All receptors reduce calcium currents and µ-receptors increase 
additionally potassium current. Physical addiction is predominantly mediated 
via µ-receptors and to a lesser extent via κ-receptors. Tolerance is an important 
issue as especially the central euphoric effect needs increasing doses of an opi-
ate to maintain a constant effect. A δ-receptor-agonist would be a relatively se-
lective analgesic, which unfortunately does not yet exist. However, noscapine 
(used as an antitussive) lacks activation of µ-receptors.  
Heroine is very dangerous with an extremely high toxicity and addiction poten-
tial. It is rapidly metabolized to 6-mono-acetylmorphine and morphine and 
some other metabolites. Usual doses are 75-200 mg, but deaths were already 
observed with 10 mg (in drug-naive persons). Therapeutic doses - in special 
substitution programs - start with 5 mg.34 The user pays about 50 Euro per g 
heroine (middle quality of brown heroine). White heroine may be more expen-
sive (personal information). As in general young people with low or even no 
income are affected by drug dependence, this fact may warrant special pro-
grams to reduce concomitant life threatening risks such as HIV or promiscuity. 
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In routine clinical use many patients benefit from the analgesic or antitussive 
effect, sedation, reduction of gut peristalsis in case of diarrhea or even im-
provement of dyspnea in palliative care. However, respiratory failure in over-
dose is life-threatening which needs immediate ventilation or administration of 
naloxone (non-selective, competitive antagonist; note: repeated doses may be 
necessary due different half-lives). Withdrawal can cause vital complications 
due to the excessive secretion noradrenaline and may require sedation and/or 
clonidine. It is important to know that naïve patients and drug users a quite dif-
ferent. To illustrate this: a patient with pain needs buprenorphine in a dose of 
0.2 mg sl. However, drug addicted get 2 to 4 mg, even up to 24 mg per day.35 It 
can be dangerous to dose naïve patients with doses adequate for chronic con-
sumers. Harold Shipman used high doses of heroine – in addition to other opi-
oids - to kill his patients, which is 2 to 3 times more potent with the regard to 
morphine and especially dangerous when applied intravenously. Even 30 mg iv 
– starting doses are 2.5 or 5 mg per os – can be lethal. However, the detection 
of opioids in the buried corpses was a real challenge.36    





Amphetamines and derivatives including modern designer drugs act via secre-
tion of neurotransmitters such as noradrenaline, serotonine or dopamine.37 
They antagonize tiredness, cause euphoria or improve self-confidence (“uppers 
or pushers”) and reduce appetite. Some derivatives are in clinical use for obesi-
ty, narcolepsia or ADHS (e. g. methylphenidate or dexamphetamin). Although 
small doses of “speed” or similar drugs do not cause a serious toxicological 
problem – apart from psychosis, which occurs in up to 30% of users -, high 
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doses (“binges”) can result in life threatening cardiovascular sequelae such as 
arrhythmia, especially in non-adapted users.38 Doses of 100 mg up to 1000 and 
more – therapeutic doses of dexamphetamine for narcolepsia or ADHS are 2.5 
to largely 20 mg! - can be considered as dangerous, particularly when given iv.  
 
Withdrawal symptoms (predominantly psychic addiction) are generally mild 
but long-term use can lead to depravation and social decline. Indirect vital 
threats are hypoglycemia or exsiccosis due to somatic exhaustion. One should 
not forget the risk of depression after cessation of stimulant effects which in-
crease the risk of suicide. An important drug interaction is the combination 
with SSRIs or MAOIs, as both classes of drugs may increase the serotonin lev-
el in the synaptic cleft.  
Major toxicological risk: Psychosis including associated accidents, depression 




Ecstacy (MDMA) and other amphetamine-related designer drugs affect partic-
ularly serotonine and noradrenaline secretion, which explains their hallucino-
genic properties (“entactogen, empathogen”). It was already synthetisized in 
1922, when a local hemostyptic was looked for.38  Since the 60ies it has be-
come more popular and a common rave drugs in young people. In “normal” 
doses of 50 to 200 mg hyperthermia, exsiccosis and sometimes aggression are 
the most important side effects.39 However, higher doses and impurities can al-
so lead to fatal heart failure or arrhythmia. One should not forget that combina-
tion with drugs elevating serotonin (such as SSRIs or Monoaminooxidase in-
hibitors, even opiates such as tramadol) can cause serious serotonin syndromes.  
Major toxicological risks: exsiccosis, hyperthermia, hypertension, interaction, 
serotonin syndrome 





Cocaine also possesses stimulant effects but is chemically and pharmacologi-
cally different from amphetamine.38 Cocaine predominantly inhibits reuptake 
of catecholamines and has local anaesthetic effects similar to procaine (blocks 
Na+-channels). Already 50 mg systemically applied can cause epileptic fits or 
respiratory failure. Bad adverse events due to its constrictive properties are na-
sal necroses, stroke and heart attacks even in young people. The addictive po-
tency is quite higher compared to other stimulants, notably for crack (cocaine 
plus baking powder). Chronic use leads to depravation, social decline, change 
of personality or even psychosis.  
 
Renal failure, rhabdomyolysis, liver impairment or even cardiovascular crises 
including arrhythmia often require ICU treatment. Lethal oral doses for begin-
ners are approximately 0.5 to 1.3 mg per day, chronic users may tolerate daily 
intakes up to 5 mg.40 The price for the addict is approximately 90 Euro per 
gram (personal information). 
 
Withdrawal is much more severe compared to amphetamines including tachy-
cardia, exhaustion, transpiration or psychosis as well as depression with in-
creased rates of suicide.   
Major toxicological risks: drug-induced psychosis, heart failure, stroke, sep-




The major active compound in cannabis (Cannabis sativa, hemp) preparations 
is tetrahydrocannabinol (TCH). Usually, hashish derives from the resin of fe-
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male blossom and contains 2 -10 % THC, marihuana from dried blossoms 
(“gras”) and contains up to 30% of THC.41,42 THC (and endogen agonists such 
as anandamide) can stimulate cannabinoid receptors - CB1, CB2-, CB1 affect-
ing mainly the nervous system and CB2 the immune system.  
 
CB1 stimulation increases Ca-channel activity influencing associative learning 
and neuronal plasticity. The minimal dose of THC in normal “use” is about 5 
mg, a cigarette ("joint") may have about 1g marihuana containing 25 mg of 
THC  with an absorption of 60% .42  Cannabis is not harmless. 2g injected iv in 
70 kg person can be lethal. 
 
Agonists have been developed, such as rimonabant for overweight or addiction 
[no longer on the market], SativexR spray (THC and cannabidiol; usual dose: 
one puff contains 2.7 mg THC and 2.5 mg Cannabidiol, maximum: 12 puffs 
per day, expert information), which alleviates spasticity in patients with multi-
ple sclerosis, or dronabinolR (THC solution) in the treatment of severe pain 
(normal dose 2.5 to 15 mg, maximum about 50 mg).43  
 
“Spice” contains synthetic cannabinoids which bind to the CB-receptors; ex-
amples are JWH-019 or JWH 073 (note: JWH stands for J. W. Huffman, the 
inventor of the chemicals, sometimes allocated to the NPSs) and were sold as 
incense material.44 However, spice preparations (mixture of cannabinoid ago-
nists) were forbidden in the UK in 2009 and – due to the number of alterna-
tives - the government initiated the Psychoactive Substance Act in 2016, which 
bans all spice variations.  
 
The effect of the cannabinoids depends very much on personal factors and 
emotions.45 The drug can be smoked (joints) or taken orally (tea, cookies). Ra-
re but dangerous is the intravenous administration of a cannabis broth which 
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leads to the serious “intravenous marihuana syndrome” with fever, myalgia, 
nausea and vomiting.46 Inhalation is effective within minutes and lasts up to 5 
hours, after oral intake the effect is delayed. The users feel relaxation, well-
being, euphoria, altered perception as well as a altered sensation of time and 
slight tachycardia, conjunctivitis, slurred speech and ataxia or nystagmus. After 
chronic use an amotivational syndrome with self-neglect provokes social de-
cline. Although the toxicity is low and withdrawal syndromes are mild, schizo-
phrenia-like severe psychosis may occur in chronic users and drug-induced hu-
bris may be fatal; the drug also facilitates a switch to “hard” drugs, although 
the majority of the users will not switch. Moreover “bad trips” or flashbacks 
(even weeks after intake) may impend. What should never be forgotten: Smok-
ing risks of joints do not differ from cigarettes and likewise the unborn child 
can be affected.45 
Major toxicological risks: psychosis and faulty actions, high intravenous doses 




Hallucinogens are a heterogeneous group of compounds, often phytotoxins 
from plants, which more or less facilitate serotonin effects.47 The most known 
representatives are LSD (claviceps purpara), mescalin (ingredient of cactus), 
psilocybin (fly aminita) or phencyclidin (PCP, synthesized from ketamine, a 
NMDA-receptor blocking narcotic, some, see below). The initial effects are 
vertigo, palpitation, mydriasis or tremor. Then affect may sway up and down 
and is followed by predominant visual hallucination with intensive perception 
of colour, hubris and loss of reality. Flashbacks can be very inconvenient. 
“Normal” doses of LSD (formerly DelysidR from Sandoz) are 20 to 200 mg, 
the effect starting 2-3 hours after oral administration. The half-life is about 2.6 
page 30 of 76 
 
hours, the effect lasts up 8 hours with a 100 mg dose. Although it has a low 
addiction potential, action slips are a real - even vital- danger.48 
Major toxicological risks: faulty actions due schizophrenia-like psychopathol-
ogy 
 
Sedatives and Hypnotics 
 
Sedative or hypnotic drugs are a heterogeneous group used clinically widely to 
facilitate sleep, to calm down (“downers”), to reduce excitation, muscle spasms 
or withdrawal symptoms. Some of these drugs play a major role in anesthesia 





The most popular group of sedatives are the benzodiazepines which on the 
market since the early 60ies. They affect the GABA-chloride-channel-complex 
- influx and hyperpolarisation - leading to a reduced excitability of neurons.49 
  
There are compounds with very short HL (midazolam, 2-3 hs, active metabo-
lite), mean HL (lorazepam, 10-20 hs, no active metabolite, dose 1 to 4 mg per 
day) or long HL (diazepam ,up to 100 hs!, including active metabolites, dose 5 
to 30 mg per day). Common side-effects are dizziness, coordination problems, 
addiction or ataxia (risk of falls). However, toxicologically they are considered 
as relatively safe, although respiration failure, especially when combined with 
drugs or alcohol may cause vitally dangerous complications. Fortunately, the 
effect of benzodiazepines can be antagonized by flumazenil (0.5 to 1 mg ini-
tially, but the half-life of 40 to 80 minutes may shorter than that of the benzo-
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diazepine). The withdrawal can cause delirium and must be done very slowly 
over weeks due to the risk of fits. 




Barbiturates were popular before the benzodiazepine era in 1960ies. They – 
like the benzodiazepines – bind to the GABAa-receptor but another site of the 
complex. In higher doses they cause coma and respiratory failure, which make 
them extremely dangerous in contrast to benzodiazepines. Occasionally, one 
can observe barbiturate blisters (personal experience). ICU-treatment is gener-
ally necessary to warrant ventilation; moreover, forced alkaline diuresis – bar-
biturates are derivatives of the barbituric acid – promotes renal excretion of 
barbiturates. Therefore, they are no longer used as sedatives but derivatives 
such as thiopental and methohexital or phenobarbital (approximately oral dose 
of 30 to 200 mg per day) fulfill a purpose in anesthesia or as antiepileptics, re-
spectively.49,50  The lethal dose may be 2 to 10 g, but is much lower in combi-
nation with alcohol.51 
Withdrawal can be complicated by vomitus, collapses or vegetative reactions 
or even delirium and fits. Therefore, the dose must be tapered carefully.  
Major toxicological risks: respiratory failure, hypotonia, withdrawal, alcohol 
interaction   
 
Planttoxins and fungal toxins 
 
A plenty of plants or mushrooms are used from time to time from addicted, 
may be accidental or deliberately. Some of them have quite regularly relevance 
in clinical toxicology, although “general unkown diagnostics” is necessary.52 
Popular plants are the angel trumpet, belladonna, henbane or mad apple. They 
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exert an atropine-like effect such as atropine itself (LD50 90 mg after iv-
administration in mice19; already 10 berries of banewort may be fatal!) or sco-
polamine, leading to tachycardia, mydriasis, urinary retention, hyperthermia, 
hallucinations or delirium. Physostigmin may be an adequate antidote for such 
emergencies. Cardiac problems can be a vital threat as could be hyperthermia. 
Fatal accidents or self-mutilation can occur. There is no clear dose-response-
relationship which make the toxic effects hardly predictable.  
 
Chronic use can lead to some kind of dependence relatively mild withdrawal 
symptoms such as nausea, vomitus or transpiration. 
Major toxicological risks: hyperthermia, cardiac problems, accidents due to 
delirium.   
 
The toxicological “mirror image” of atropine-like drugs are inhibitors of the 
cholinesterase or agonists of acetylcholine such as muscarin, physostigmin or 
arecolin. Such alkaloids are found e. g. in betel nuts or calabar bean. Here, at-
ropine is the usual antidote. Such intoxications, however, may be fortunately 
very rare. 
 
Thinners and sniffers (volatile compounds) 
 
Simple and complex hydrocarbons such as benzene, acetone, butane or xylene, 
toluol, amylnitrite (“Poppers”) and chloroform are widely available. The com-
pounds are used in the industry (clue, solvents, petrol, nail varnish remover, 
propellants etc.) and comparably cheap [personal experience: sniffing teenag-
ers in Sao Paulo is a catastrophy]. They can be inhaled from bags with the fluid 
or just from a cloth soaked with the thinner. 53 They non-specifically increase 
unit membrane permeability leading to euphoria, confusion, slurred speech and 
blurred vision or misperception.54 Very dangerous can be cardiac arrhythmias, 
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laryngeal edema or acute suffocation due to hypoxia if only the oxygen defi-
cient contents of the plastic bags is inhaled. Long-term use can cause 
encephalopathies, polyneuropathy and liver or kidney impairment. Multi-organ 
failure is possible with sudden death. Withdrawal similar to alcohol can occur.  
Major toxicological risks: acute hypoxia, polyneuropathy, cardiac arrhythmia 
 
9 New Psychoactive Drugs 
 
Designer drugs - also called “Legal Highs, New Psychoactive drugs (NPD), 
New Psychoactive Substances (NPS) or Research Chemicals”- can be easily 
synthesized in labs, like the name already indicates "tailor-made".55 The con-
cept of Legal Highs is very delusive and the law may lag behind the scene and 
the illegal inventive talent of drug labs. Some NPSs are summarized in table 8. 
 
Startung from a basic structure, e.g., amphetamine, morphine or LSD, are gen-
erated using relatively simple reaction steps and an almost infinite variety of 
new drugs can be produced. With regard to amphetamine derivatives, a back 
room might be sufficient as a rule. Probably, there exist more than 1000 varia-
tions („chemical hydra“) and per year more than 50 new psychoactive sub-
stances flood the “drug market”.56,57  
 
Designer drugs in the narrower sense are not new as one might think. Some 
were synthesized in the 1920s, some were forgotten and re-discovered some 
years ago (e.g. mephedrone). Loi and coworkers have analyzed fatalities in 
teenagers and young adults (16-24 years) after use of mephedrone between 
2009 and 2013 in the UK.58 30 young people died (73% male), all being of 
white ethnicity, and 85 % had a history of drug use. 63 % of the cases were 
considered as accidental poisoning and other drugs may be involved in some 
60% of the deaths.  
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Because many of these substances of this group of the stimulants are assigned 
as "recreational drugs", it seems very tempting to consume this stuff as doping 
agents – especially in young adults!59 Unfortunately, the effect of NPSs cannot 
always be foreseen, the structure does not correlate with the effect. E. g. the 
synthetic cannabinoides in Spice differ structural-chemically from 
Tetrahydrocannabinol in the marihuana, so that no real analogical conclusion is 
possible.55  My personal experience with “Flakka” is as follows: fully awake at 
3 a.m., wide pupils, massive aggression and force (6 officers necessary), no 
chance of even basic communication and screaming, optical hallucinations and 
paranoid thoughts (absolute misinterpretation of environment, transpiration and 
fever (39 C°), flush, duration of about 6 hours, slight response to benzodiaze-
pines and antipsychotics.  
 
The chemical hydra impedes the work of the legislation and authorities, as the 
imagination of the adulterators is endless. The Internet contributed substantial-
ly to the spreading of these substances, partly in disguise as "research mole-
cules", "plant food" or "bath salts" with a professional appearance and nice 
names like "Bromo-DragonFly" or "China White".  
 
The high rate of new substances contribute massively to the vital danger of 
consumers, because no scientific experiences with the substances are given. 
The easy production of the NPDs lowers their price – partly cheaper than alco-
holic beverages in an order of 10 Euros for a “line” - what leads, in addition, to 
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No unique definition of NPS exist and the lists vary from source to source. As 
almost every week new NPSs are produced, one should not be surprised. How-
ever, I used the information of EU und WHO as a guideline and added infor-
mation from literature.61 
 
Effect and pharmacology 
 
We know only the exact pharmacology from some new NPSs, from some poi-
sons not even the exact ingredients, what still raises the hazard potential. Bath 
salts resemble pharmacologically to the amphetamines and the effects change 
according to composition of the stuff and the penetration through the blood 
brain barrier.62 Methylendioxypyrovaleron (MDPV), methylon or mephedron 
(class of the cathinones) can hide behind the false mask of bath salts. Common 
to all compounds is a considerable addiction potential. The concentrations of 
the mono- amines (serotonin, noradrenalin, dopamine) in the synaptic gap rise 
after intake of bath salts. 
 
“Flakka”, also called "zombie's drug", (MDPV, see above) inhibits mainly the 
re-uptake of noradrenalin and dopamine and causes especially heavy hyperac-
tive psychoses with faulty actions, mostly aggressive assaults ("exited 
delirum"), which may continue several hours.63 A compound with similar 
structure and effect is alpha-Pyrrolidinopentiophenon (alpha-PVP) [sometimes 
also called Flakka]. Bromo-DragonFLY is a derivative of the DOB (2,5-
Dimethoxy-4-bromamphetamin) which itself is to be classified as the potent 
psychodelic hallucinogenic. Like LSD it works mainly as a serotonin ago-
nist.64,65  
 
To the same group of hallucinogenic chemicals belongs the "N-bombs" (25I-
NBOMe), which was synthesized recently in 2003.66  Probably, this drug has to 
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be classified as psychodelic hallucinogenic with is more dangerous and has the 
risk of fatal cardiac complications as a result of  vasoconstriction.67 Another 
hallucinogenic is Demethyltryptamin (DMT).68,69 In particular, after oral intake 
DMT is in praxi often combined with natural occurring  MAO-inhibitors such 
as passion flower or ayahuasca extracts which reduces the metabolic capacity 
of the liver, in order to slow down elimination of DMT 
 
A hallucinogenic of “special kind” is Jenkem which is inhaled for usual. It is 
won from human excrements after a fermentation process and was “discov-
ered” in Zambia, where it threatens the welfare of the youth. The pharmacolog-
ical knowledge is rare. Some investigations state that it resembles to the sew-
age gas or decayed gas. The gas works for approximately 1 hour intensely as 
an auditory and optical hallucinogenic. As we know from thinners 
(“inebriantia”), the vital risk of the acute hypoxia exists, too, when it is inhaled 
from plastic bags.70,71 
 
"Crocodile" or "Krok" (desomorphine) was already synthesized in 1932 and 
was first destined for a potent a quick and effective opiate.72 However, in the 
synthesis process, among other compounds, the combination of 
pseudoephedrin beside phosphorus and iodine leads to an extremely toxic mix-
ture. The results are horrible phlebitides, thromboses, osteomyelitis, muscle 
and skin ischemia and complicated organ damages with gangrenes liable to 
amputation.73 
 
Kratom, a plant essence of the Kratom plant (ingredient mitragynin), played a 
role already in 19th century in Indo-China, shows an effect similar to codeine 
and, in the past, was used as an analgesic in Asia. it can cause severe with-
drawal syndromes.  The sage of deviners (“magic mint”) stimulates opioid re-
ceptors (kappa). The ingredients (salvinorines, orignally from central America) 
page 37 of 76 
 
are supposed to be the strongest natural (biological) hallucinogenic com-
pounds.74. 75 
 
The list of NPSs is by far not complete – some sources add new benzodiaze-
pines or ketamine-derivatives as well as spice to the list - , it is just a first step 
to understand the danger of this terrible development. Further information on 
NPSs are e. g. available at the WHO (United Nations Office on Drug and 
Crime or The DrugWise homepage).76,77 
 
10 Legal compounds for illegal use 
 
Some drugs which are in clinical use can be nonetheless used in an illegal way 
by drug addicts. One common example is ketamine or sometimes its enantio-
mer esketamine- also used in veterinary medicine- , which is twice as potent. It 
has some structural similarities with pethidine and PCP. It is used as an anes-
thetic but has a hallucinogenic and  a dissociative property, and is therefore 
combined with benzodiazepines.78  Recently, it gains importance in the treat-
ment of depression [personal experience: can be given successful as nasal 
spray]. It is a NMDA-receptor antagonist with some effect on catecholamine 
re-uptake. Dissociative anesthesia using ketamine (combination with benzodi-
azepine due to bad dreams) means spontaneous breathing, good analgesia 
without hypotonia and maintenance of preventive reflexes. What makes the 
drug “interesting” is of course its larger therapeutic index and that ketamine 
could be sniffed nasally, given orally or into muscle or vein and even sublin-
gually. After administration the effects lasts up to 2 hs, after oral intake up to 
approximately 5 hs. Unfortunantely, ketamine has gained importance as a party 
drug under names such as K, Kate, Special K, Fiction or Kitty. However, hor-
ror trips, bad tunnel visions and near death experiences – and hypertension 
with the risk of cardiovascular events - limit its illicit use.   
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Gamma-hydroxy-butyric (GHB) acid belongs to the group of oxybates and is 
known in the drug scene as "liquid ecstasy, fantasy etc.". It is often misused as 
“date rape drug”, and you should be cautious on parties with drinks.79 GHB 
works both as an intrinsic neurotransmitter and a partial agonist of the GABA-
A-receptor, being structurally related to GABA. It is metabolized very rapidly 
– the active metabolite is OH-crotinic acid - so that it can be detected in urine 
only up to 12 hs and in blood up to 8 hs, which must kept in mind in emergen-
cy situations. Moreover, it causes amnesia, which makes it often impossible for 
the victim to remember the felony. It is, however, used as a narcotic (Somsa-
nitR) and in narcolepsia with a good effect for cataplexia (XyremR) - doses 4, 
5 to 9 g per day - in some countries (patient information sheet). However, 
Xyrem contains a lot of sodium! 
 
Etizolam (EtilaamR) and phenazepam (developed in Russia) or flunitrazeapam 
(RohypnolR, “forget-pill, R2, ruffies”) are benzodiazepines  with affinity to the 
GABAa receptor and a relatively high addiction and withdrawal potential. The 
compounds are used in some countries as anxiolytics, antiepileptics or anaes-
thetics. The compounds have a very high addictive potential compared to usual 
benzodiazepines.80 The drugs were allocated to Class C according to British 
law and generally are not used in clinical practice.   
  
Caffeine – a methylxanthine - in very high doses is an inhibitor of the 
phosphodiesterase (PDE) and inhibits adenosine receptors.  Therefore, it is re-
lated to the asthma therapeutic theophyllin and can be used for this purpose. 
Many of us use caffeine-containing beverages “to wake up” in morning.  How-
ever, if one admits that a cup of coffee contains about 50 to 80 mg of caffeine, 
largely 75 to 100 cups of coffee – or the equivalent dose of caffeine adminis-
tered - can cause serious cardiac problems, approximately 10 g being really a 
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toxicological threat. We must add that caffeine powder is also sniffed by abus-
ers and is then faster effective and more bioavailable compared to oral in-
take.81,82   
 
11 Dying from drugs – A clinical view 
  
How can drugs kill humans?  First of all, the drug can kill a human being di-
rectly such as an overdose of heroin or barbiturates leads to respiration failure 
or a thinner to cardiac arrhythmia. Secondly, the use of a drug can facilitate 
complications such as an epileptic seizure after intake of amphetamines or high 
doses of caffeine. In the third place, withdrawal may lead to fatal cardiovascu-
lar failure or a serious fit after stopping alcohol. In the fourth place, physical 
mechanisms such as squeezing out oxygen from a bag with thinner can cause 
hypoxia. In the fifth place, fatal accidents due to ataxia or paranoia (“I can 
fly”) or hubris may cause death. In sixth place, long-term complications such 
as lung cancer (not only tobacco but all smoked stuff) or liver cirrhosis or HIV 
(risk of promiscuity) or cerebral bleeding or heart attacks (cocaine) can lead to 
death. One should not forget that suicide rates are higher in addiction com-
pared to normal population. Another source of deaths are pharmacological in-
teractions – e. g. AntabusR (disulfiram) effect or serotonin syndrome – when 
users combine drugs or patients on tramadol take an SSRI. Occasionally, 
preexisting diseases (e. g. diabetes or coronary heart disease) may be a substan-
tial factor such as death due to ketoacidosis or acute heart attack and arrhyth-
mia due to long QT-syndromes. Some addicted die from traffic accidents or 
even due to action slips or confusion, e. g. if they consume methanol instead of 
ethanol or fatal contamination. Finally, one must be aware of the fact that those 
who suffer from addiction have a higher risk of becoming a victim of fatal as-
saults. One should also not forget the children who suffer or even die, if the 
drug-affected parents are no longer able to care for them. So the question of 
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death caused by drugs is complex and not always easy to answer. It is however 
always important that drugs can lead to a false premature diagnosis of death 
and intoxications should be excluded or technical devices be used. Among oth-
ers, it is the duty of the coroner or procurator fiscal in Scotland to unravel this 
bundle of questions. 
 
12 Prevention strategies 
 
It is not the purpose to review therapeutic interventions as excellent textbooks 
with detailed standard procedures exist, e.g. the work of Ries and colleagues, 
which I cited repeatedly. I must underline that the efforts against all statistics 
were successful in the last 20 years. For years, police, judges, coroners, social 
workers, educators or doctors try to improve the self-efficacy of generations 
and make young people resilient against any fatal temptations. The struggle 
was not all in vain, however, many consumers do not get rid of the drug. 
 
If somebody accepts treatment – and this is a real obstacle – he has a chance of 
about 50 % to live abstinent from alcohol or drugs. The data are slightly worse 
for illegal drugs compared to alcohol, but comparable in developed countries. 
In praxi, we often get them out of criminal milieus, too. But this is not enough, 
the struggle must go on. To have stricter laws, does that help? In the UK in 
2016 128260 offences had been documented, in Germany 229227, in Italy 
61145 offences (EU-report).83 Obviously, laws or “war against drugs” cannot 
solve the problem alone. A British study is dubious about the role of laws or 
repression with regard to control of consume of hard drugs, particularly.84 Italy 
has the lowest substitution rate but also the lowest death rate due to drugs. 
Simple answers do not exist. A wise measurement is the Drug Arrest Referral 
Scheme of police, which is encouraged by PACE.7 It offers drug users low 
threshold and confidential drug program in the custody unit. 
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When I think of my patients, they are young, they have problems to become 
adults, to learn a profession, they have problems with their relationships and 
they have no real aim for their live or "common sense". Approximately 2/3 
may be male. Modern communication – which is in realiter no personal com-
munication – alienate the young generation from each other. They mostly have 
no idea that drugs can hurt and they tend to trivialize the risk. In general, they 
have no idea, what a risk is. What is more evil, air pollution or smoking habits? 
Of course, smoking habits The answer is scientifically clear, but even politi-
cians ignore the facts, although I support the struggle for better air.  
 
The author suggests that the relevance of the core family has changed. A plenty 
of young adults lack intact family structures. Why does Italy cope with the 
problem better than the UK or Germany? May be that the joint family gives 
self-confidence and emotional protection. In conjunction with this dilemma, I 
got the impression that activities in the local football club or other community 
based groups has diminished in the last 20 to 30 years also in my country.  
 
What was surprising for me is the fact that more rural regions – Bavaria in 
Germany and Wales in the UK – have very high drug related death rates (Fig-
ures 6 and 7, table 9).85,86  London or Berlin are not so much affected than rural 
regions? Good air, silence or a nice landscape do apparently not exert a preven-
tive effect. However, if you look on the table of German states, eastern Germa-
ny has a significantly lower rate of drug-related deaths compared to the west-
ern part? What does that mean? Even the Czech Republic with its drug labora-
tories – SN (Saxony) is in the neighborhood of the Czech Republic- does not 
increase the death rate, but the Netherlands with their liberal drug politics 
(neighborhood or NW (Northrhine-Westafalia) do?  Or is it the real purchase 
power which is still better in the western states? However, I doubt that Wales 
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has more purchase power than London. What is the difference between the 
East Midlands and two northern regions of England? What is the reason for the 
high rates in the North East and North West counties? Many questions remain 
open and the data base is too weak in order to jump into conclusions.  
 
Last but not least, ethical considerations are important. All those engaged in 
prevention walk a fine line between autonomy of the consumer, paternalism, 
beneficence and moral duty. In a liberal democratic society the struggle against 
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Table 1: Number drug-related deaths in England and Wales between 2012 and 
















Table 2: Drug-related deaths in Scotland according to the ONS between 2006 
an 2016 (source: https://www.nrscotland.gov.uk/statistics-and-
data/statistics/statistics-by-theme/vital-events/deaths/drug-related-deaths-in-












Table 3: Drug related deaths in Northern-Ireland between 2006 and 2016 ac-
cording to death certificates (source: https://www.nrscotland.gov.uk/statistics-
and-data/statistics/statistics-by-theme/vital-events/deaths/drug-related-deaths-











Table 4: Comparison of drug-related death rates in different countries aged 15 
to 64 years – latest statistics.  
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
All Opioids 41 35 35 37 52 54 67 71 63 88 90 633
Heroin/Morphine* 12 10 6 9 16 17 24 25 11 27 25 182
Methadone* 2 1 1 1 3 4 5 5 8 6 8 44
Tramadol 11 11 11 8 13 17 31 20 22 28 33 205
Codeine not from compound formulation* 9 16 14 8 17 15 22 22 19 13 17 172
Dihydrocodeine not from compound formulation* 14 9 11 17 10 9 8 5 8 13 18 122
Oxycodone 1 4 1 4 9 6 2 9 8 12 10 66
Fentanyl 1 2 - 1 6 3 7 4 1 15 13 53
Cocaine* 1 3 6 4 3 5 4 1 8 8 3 46
All amphetamines* 2 5 4 4 2 4 4 1 11 7 8 52
    MDMA/Ecstasy* 2 5 3 3 1 2 4 1 7 4 7 39
Any psychoactive substance** - - - 4 2 2 2 4 19 16 7 55
Cathinones (includes Mephedrone) - - - - 1 2 2 3 8 7 1 24
All benzodiazepines* 26 29 35 28 40 36 47 47 45 63 65 461
    Temazepam* 4 8 6 1 3 1 4 - 1 4 2 34
    Diazepam* 20 21 28 22 35 34 42 40 42 58 60 402
Pregabalin - - - - - - - 1 5 7 8 21
All antidepressants 25 20 27 27 22 20 28 27 30 38 39 303
Mirtazapine 4 3 5 2 6 4 6 5 11 11 13 70
Tricyclic antidepressants (TCA) 15 11 15 18 10 10 11 11 13 19 17 150
    Dothiepin 4 4 6 5 2 3 6 3 - 3 1 37
    Amitriptyline 9 7 8 9 8 4 4 9 12 17 15 102
Selective serotonin re-uptake inhibitors (SSRI) 5 7 6 5 7 6 10 7 6 7 8 74
Paracetamol (includes dextropropoxyphene or 
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Table 5: Maximum penalties for possession, supply or production of different 










Crack cocaine, cocaine, ecstasy (MDMA), her-
oin, LSD, magic mushrooms, methadone, 
methamphetamine (crystal meth) 
Up to 7 years in pris-
on, an unlimited fine 
or both 
 
Up to life in 
prison, an un-




Amphetamines, barbiturates, cannabis, co-
deine, ketamine, methylphenidate (Ritalin), 
synthetic cannabinoids, synthetic cathinones 
(eg mephedrone, methoxetamine) 
Up to 5 years in  
prison, an unlimited 
fine or both 
 
Up to 14 years 




Anabolic steroids, benzodiazepines 
(diazepam), gamma hydroxybutyrate (GHB), 




Up to 2 years in pris-
on, an unlimited fine 
or both (except ana-
bolic steroids - it’s not 
an offence to possess 
them for personal use) 
Up to 14 years 








Some methylphenidate substances 
(ethylphenidate, 3,4-dichloromethylphenidate 
(3,4-DCMP), methylnaphthidate (HDMP-28), 
isopropylphenidate (IPP or IPPD), 4-
methylmethylphenidate, ethylnaphthidate, 
propylphenidate) and their simple derivatives 
None, but police can 
take away a suspected 
temporary class drug 
Up to 14 years 
in prison, an 
unlimited fine 
or both 
*The government can ban new drugs for 1 year under a ‘temporary banning order’ while they de-
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Table 6: Comparative acute toxicological data of some common drugs.19,20  
Note 1: Ricin was added for comparison. It was used in the cold war to kill re-
gime critics with primed umbrellas; LD lethal dose. Note 2: No data are avail-
able about Nowitshok. However, acc. to Wikipedia it has the toxicity (AchEI) 
of about 1/7 of VX poisons, i.e. about 1 ug/kg after iv-administrations in rats 
[source: https://de.wikipedia.org/wiki/Nervengift. assessed 04.04.2018)     
Drug Route LD50 
[mg/kg BW] 
Species 
Heroine Intraven 21.8 Mouse 
Methadone Oral 70.0 Mouse 
Cocaine Intraven 16.0 Mouse 
THC Oral 482.0 Rat 
Nicotine Oral 3.34 Mouse 
Ethanol Oral 3450.0 Mouse 
Diazepam Oral  500 Mammal 




Amphetamine Oral 21.0 Mouse 
MDMA Oral 325.0 Rat 
Caffeine Oral 200 Rat 


















Table 7: Examples of half-lives and metabolites.25,89,90  Abbreviations:  
2-Ethylidene-1,5-dimethyl-3,3-diphenyl pyrrolidine (EDDP) and 2-ethyl-5-
methyl-3,3-diphenylpyrrolidine (EMDP) 
 
Drug Half-life [hs] Metabolites 
Amphetamine 6-12 hs - 
Metamphetamin 6-12 hs Amphetamine 
Cocaine Approx. 0.5-1 hs  




Diazepam 35-55 hs ; 




Gamma-OH-butyrate 40-60 minutes Succinic acid, ß-
oxidation 
Heroin 2-8 minutes 6-Mono-acetyl-
morphine, morphine 
Morphine 2-3 hs glucuronide 
Codein 1,5, Codein-6-
glucoronide: 2,75 hs 
Morphine, 
glucuronide 
Methadone 15-55 hs EDDP, EMDP 
THC Infrequent: 1,3 d 
Chronic:  5-13 d 
TCH-COOH 
Infrequent: 2-7 days 
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Table 8:  Sample of „New Psychoactive substances on the European „market“ 
(sources: see text and 91). Further new psychoactive drugs are listed in the Na-
tional Records of Scotland (source: https://www.nrscotland.gov.uk/statistics-
and-data/statistics/statistics-by-theme/vital-events/deaths/drug-related-deaths-
in-scotland/2016. Accessed 23.03.2018 96) 
Drug Class Effects and major risks 
JWH-019, 
„Spice“ 
Cannabinoid Similar to cannabis products 
(THC) with elation, intensive 
perception und experience, par-




Bath salts Cathinone: z. B. 
Mephedron, Me-
thylon, α-PVP  
Powerful stimulants, which re-
semble cocaine or ecstasy: hallu-
cinations, Panic, delusions; sym-




















Hallucinogenic effect with disso-
ciative complications (e. g. de-






Resembles LSD;  Duration of ac-
tion up to 96 H, risk of gangrene 
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Table 8 continued 
N-Bomb Agonist of Sero-
tonin 
Resembles to LSD effects. Much 




tonin (+ MAOH) 
Hallucinogen compound without 






Powder with primarily hallucino-
genic effects. 20 mg suffice to 
cause an action for 12 hours 
Kratom Mitragynin (κ- u. 
μ-Agonist) 
Resembles effects of codeine. 
Risk of serotonin-syndrome 
(MAOH), Pigment depositions on 




gen; risk of hypoxia 
Crocodile  Opioide  (Deso-
morphin) 
Risk of gangrene, thrombosis, 
pneumonia, phlebitis or sepsis 
Etizolam Benzodiazepin Benzodiazepine with high addic-





High doses with risk of epilepsia, 
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Table 9: Distribution of drug related deaths in Germany according to states and 
free cities in 2013. Important is the “Gesamtzahl der Todesfälle” i. e. the total 
number of deaths. Northrhine Wesfalia (Ruhr-region NRW) and Bavaria (BY) 
have the highest frequency of deaths, Berlin (Be) has much lower figures. 
Source: http://ixd-hof.de/blog/2014/02/12/dokumentation-drogentote-in-


















Figure 1: Age-specific mortality rates for deaths related to drug misuse be-
tween 1993 and 2016. Increase is almost entirely due male deaths, female 
deaths being largely constant. The total absolute figure of drug-related deaths 















Figure 2:  Trend of drug-related deaths in Scotland given as 3- and 5-year mov-


























Figure 3 a-d: Mortality rates up to 2016 top down in the UK, Germany, France 
and Italy. Obviously, Germany and the UK have similar problems, whereas 
France has much lower figures and Italy a reduction of drug related deaths (see 
page 70 of 76 
 
text). Source: European Drug Report, Lisbon 2017: 







Figure 4: The figure summarizes the neurotransmitter systems involved in intoxi-
cation, preoccupation and withdrawal, the 3 stages of addiction. The neurotrans-
mitter noradrenaline is not shown but secreted in the amygdala in case of with-
drawal. 
Note: Blue represents the basal ganglia involved in the Binge/Intoxication. Red 
represents the extended amygdala involved in the affect and withdrawal. Green 
represents the prefrontal cortex involved in the preoccupation/anticipation stage. 
Abbreviations: PFC - prefrontal cortex, DS - dorsal striatum, NAc - nucleus 
accumbens, BNST - bed nucleus of the stria terminalis, CeA - central nucleus of 
the amygdala, VTA - ventral tegmental area. Source: Surgeon General Report 
2016 (US) page; 
2.15https://www.ncbi.nlm.nih.gov/books/NBK424857/pdf/Bookshelf_NBK42485
7.pdf. Assessed 04.03.201814 






Figure 5: Example of Dose-Response-Curve (Probit-Analysis) from own clini-
cal data. The curve shows the increasing risk of getting dyskinesia which re-
quired administration of biperidene following administration of risperidone 
(given chlorpromazine equivalent units). The ED50 [exactly TD50) amounts to 
3.25 (SEM 0.15) CPUs (Note: the dose is given in a log10 scale (NCSS 2007; 
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Figure 7: In order to understand the distribution of drug related deaths in the 
UK , one must have an idea about distribution of the population: Source:  
https://de.wikipedia.org/wiki/Vereinigtes_K%C3%B6nigreich. Accessed 
03.03.1894  










ATC Acute toxic class. A probit based model to estimated  
  toxicity with reduced number of animals. 
ADH alcohol dehydrogenase 
AMP α-Aminotryptamine 
α-PVP α-Pyrrolidino-pentio-phenone (NPS) 
BBC British Broadcasting Cooperation 
BP  Blood Pressure (normally given as mmHg) 
BW Body Weigth 
 
CPS Crown Prosecution Service 
CPU Chlopromazine Equivalent Units (e. g. haloperidol or  




ED50 Effective Dose 50 (50 % of the individuals show a specif- 
  ic – in general wished - effect). Analogously EC50 can be  
  defined. 
F  female 
Fig  Figure 
 
H  Hour 
HAART High Active Anti-Retroviral Therapy  
page 75 of 76 
 
HR  Heart Rate (generally bpm -  beats per minute) 
LADME Liberation – Absorption – Distribution – Metabolism -  
  Elimination 
LD50 Lethal Dose 50; the dose at which half of the species die,  
  normally given as mg/kg BW. Analogously LC50 can be  
  defined. 
LSD Lyserg-Acid-Diethylamide 
OECD Organisation for Economic Co-operation and   
  Development 
 
ONS Office for National Statistics 
OTC  Over the Counter 
 
M  male 
MAOH Mono-Amino-Oxidase-Inhibitor 
MDA Misuse of Drugs Act (1971) 
MDMA 3,4 Methylene-dioxy-methamphetamine (ecstasy) 
MDPV Methylene-dioxy-Pyrovalerone 
MLD Mean Lethal Dose 
MOE Margin of Exposure (Ratio of NOEL to the estimated in 
  take in humans; therefore it is an indicator of the po- 
  tential risk) 
NOEL No observed adverse effect level 
NOEC No observed adverse effect concentration (corresponds  
  to the highest dose or concentration without toxic ef 
  fects) 
Nac  Nucleus accumbens 
NPS New Psychoactive Substances (also NPD New Psychoac- 
  tive Drugs) 
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PACE Police and Criminal Evidence Act of 1984 
PF  Procurator Fiscal (in some way similar to the coroner) 
PFC Prefrontal Cortex 
pka Acid dissociation constant (note: pka + pkb=14) 
 
sl  sublingual 
SSRI selective serotonin re-uptake inhibitor (antidepressant) 
 
TD50 Toxicity Dose 50 (dose causing an adverse effect in 50 %  
  a population). Analogously TC50 can be defined. 
THC Tetrahydrocannabinol 
TI  Therapeutic Index (defines as ED50/LD50 or ED50/TD50  
  with regard to the preclinical or clinical model) 
 
VTA Ventral Tegmental Area 
VX Highly toxic war poisons (Acetylchloline-esterase- 
  inhibitors) (“Venomous”). 
YLL Years of Life lost 
 
 
 
